T1	intervention 31 41	carvedilol
T2	intervention 56 67	candesartan
T3	condition 75 89	cardiotoxicity
T4	No-of-participants 356 361	Forty
T5	control 517 530	control group
T6	intervention-participants 503 505	20
T7	control-participants 556 558	20
T8	duration 1094 1101	21 days
T9	outcome-Measure 898 915	Electrocardiogram
T10	outcome-Measure 917 938	ultrasonic cardiogram
T11	outcome-Measure 940 950	arrhythmia
T12	outcome-Measure 952 960	troponin
T13	outcome-Measure 965 989	non-hematologic toxicity
T14	outcome 1103 1107	LVEF
T15	outcome 1211 1226	LVEDD and LVESD
T16	outcome 1373 1377	LVEF
T17	outcome 1612 1627	LVEDD and LVESD
T18	outcome 1330 1371	After four and six cycles of chemotherapy
T19	outcome 1578 1611	After six cycles of chemotherapy,
T20	outcome 1814 1857	rate of ST segment and T wave abnormalities
T21	control-value 1862 1867	80.0%
T22	outcome 1889 1921	after six cycles of chemotherapy
T23	control-value 1957 1962	25.0%
T24	outcome 1963 1996	after four cycles of chemotherapy
T25	control-value 2013 2018	10.0%
T26	outcome 2019 2051	after two cycles of chemotherapy
T27	outcome 2069 2127	reduction of QRS voltage, arrhythmia and abnormal troponin
T28	control-value 2133 2138	55.0%
T29	control-value 2140 2145	45.0%
T30	control-value 2150 2156	45.0%,
T31	outcome 2330 2369	rate of abnormal expression of troponin
T32	control-value 2374 2379	45.0%
T33	intervention-value 2432 2437	10.0%
T34	intervention-value 2252 2257	20.0%
T35	intervention-value 2271 2276	10.0%
T36	intervention-value 2294 2299	10.0%
